August 14, 2020 13:26 IST
Aurobindo Pharma has said it is expecting its proposed vaccine candidate for COVID-19 to undergo Phase I and II trials by the end of 2020, while Phase III may be undertaken during March-April next year. Managing Director of Aurobindo Pharma, Narayanan Govindarajan in the recently held earnings call with analysts said the city-based pharma major has earmarked USD 150-200 million towards capex during the current fiscal. The COVID-19 vaccine candidate underwent an evaluation by BIRAC (Biotechnology Industry Research Assistance Council, Department of BioTechnology) and was shortlisted for funding initial development.